Latest Ratios: P/E Ratio 39.7x · EV/EBITDA 21.5x · ROE 12.5%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $2.3B | $1.6B | $3.7B | $3.1B | $5.1B | $4.2B | $2.3B | — | — |
| Enterprise Value | $1.9B | $2.2B | $1.5B | $3.7B | $3.0B | $5.0B | $4.1B | $2.2B | — | — |
| P/E Ratio → | 39.74 | 39.51 | 30.26 | 59.97 | 103.83 | 76.29 | 90.19 | — | — | — |
| P/S Ratio | 1.57 | 1.78 | 1.41 | 3.44 | 3.96 | 10.09 | 12.18 | 9.99 | — | — |
| P/B Ratio | 4.48 | 4.45 | 3.90 | 6.76 | 8.26 | 20.07 | 25.15 | 20.08 | — | — |
| P/FCF | 10.55 | 11.98 | 9.48 | 20.21 | 40.36 | 211.35 | 119.40 | — | — | — |
| P/OCF | 9.63 | 10.93 | 9.19 | 19.82 | 38.73 | 194.07 | 115.98 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.72 | 1.29 | 3.37 | 3.81 | 9.93 | 12.00 | 9.64 | — | — |
| EV / EBITDA | 21.49 | 24.53 | 21.29 | 56.85 | 120.33 | 147.74 | 403.57 | 187.44 | — | — |
| EV / EBIT | 22.74 | 23.19 | 18.07 | 51.85 | 122.80 | 153.24 | 495.71 | 228.76 | — | — |
| EV / FCF | — | 11.54 | 8.66 | 19.79 | 38.90 | 207.89 | 117.68 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.6% | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% | 20.3% | 19.8% | 18.4% | 15.2% |
| Operating Margin | 6.6% | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% | 2.4% | 4.2% | -3.3% | -22.7% |
| Net Profit Margin | 4.5% | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% | -3.7% | 0.6% | -25.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.5% | 12.5% | 11.1% | 13.3% | 9.7% | 31.4% | 33.0% | -13.7% | 6.1% | -116.5% |
| ROA | 8.7% | 8.7% | 8.0% | 9.5% | 6.7% | 21.5% | 23.0% | -8.9% | 1.7% | -35.6% |
| ROIC | 18.0% | 18.0% | 13.4% | 12.6% | 8.1% | 17.6% | 8.9% | 32.2% | -23.1% | -73.8% |
| ROCE | 17.4% | 17.4% | 13.4% | 13.0% | 7.3% | 14.9% | 5.7% | 15.4% | -24.4% | -64.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.05 | 0.04 | 0.02 | 0.03 | 0.06 | — | 0.02 | 0.49 |
| Debt / EBITDA | 0.31 | 0.31 | 0.27 | 0.30 | 0.31 | 0.26 | 0.93 | — | — | — |
| Net Debt / Equity | — | -0.16 | -0.34 | -0.14 | -0.30 | -0.33 | -0.36 | -0.70 | 0.01 | 0.05 |
| Net Debt / EBITDA | -0.94 | -0.94 | -2.03 | -1.21 | -4.51 | -2.46 | -5.93 | -6.81 | — | — |
| Debt / FCF | — | -0.44 | -0.82 | -0.42 | -1.46 | -3.46 | -1.73 | — | 0.07 | — |
| Interest Coverage | — | — | — | — | — | — | — | 166.84 | -6.95 | -14.87 |
Net cash position: cash ($112M) exceeds total debt ($28M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | 2.73 | 2.80 | 3.44 | 2.72 | 2.62 | 2.45 | 3.66 | 0.81 | 0.94 |
| Quick Ratio | 2.73 | 2.73 | 2.80 | 3.44 | 2.72 | 2.62 | 2.45 | 3.66 | 0.81 | 0.94 |
| Cash Ratio | 1.53 | 1.53 | 1.35 | 2.00 | 1.19 | 1.21 | 1.41 | 2.22 | 0.00 | 0.26 |
| Asset Turnover | — | 1.74 | 1.92 | 1.44 | 1.45 | 1.40 | 1.36 | 1.53 | 2.55 | 1.39 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 62.39 | 73.59 | 81.10 | 111.35 | 98.10 | 80.08 | 74.78 | 80.77 | 85.44 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.5% | 2.5% | 3.3% | 1.7% | 1.0% | 1.3% | 1.1% | — | — | — |
| FCF Yield | 9.5% | 8.3% | 10.5% | 4.9% | 2.5% | 0.5% | 0.8% | — | — | — |
| Buyback Yield | 4.0% | 3.6% | 18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 4.0% | 3.6% | 18.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $89M | $95M | $101M | $100M | $100M | $99M | $84M | $82M | $6M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PGNY stock.
Progyny, Inc.'s current P/E ratio is 39.7x. The historical average is 66.7x. This places it at the 33th percentile of its historical range.
Progyny, Inc.'s current EV/EBITDA is 21.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.2x.
Progyny, Inc.'s return on equity (ROE) is 12.5%. The historical average is -1.4%.
Based on historical data, Progyny, Inc. is trading at a P/E of 39.7x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Progyny, Inc. has 23.6% gross margin and 6.6% operating margin.
Progyny, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Client concentration and utilization volatility
Metrics are mathematically derived from official filings.
Margin Expansion Amid Utilization Mix
Gross margin improved to 25.5% in Q2 2026 from 23.7% a year earlier, per financial statements, while operating margin expanded to 11.4% from 7.3%, suggesting favorable mix and cost discipline.
The sequential improvement in gross margin from 24.1% in Q4 2025 to 25.5% in Q2 2026 appears driven by a shift toward higher-margin Progyny Rx and controlled medical costs. Operating leverage is evident as SG&A grew slower than gross profit, but the sustainability of this trend depends on utilization rates and client retention. Net margin at 8.0% remains modest, reflecting the pass-through nature of claims and the impact of stock-based compensation.
ROIC Recovery Signals Efficiency Gains
ROIC rose to 9.1% in Q2 2026 from 3.7% a year earlier, per reported figures, while ROE improved to 6.3% from 3.5%, indicating better capital efficiency despite decelerating growth.
The sharp increase in ROIC from 2.6% in Q4 2025 to 9.1% in Q2 2026 suggests that the company is generating more operating income per dollar of invested capital, likely due to margin expansion and a stable asset base. ROE remains low relative to peers, but the trend is positive. Investors should monitor whether this improvement is sustainable as the client base matures and utilization normalizes.
Working Capital Efficiency Improves
DSO improved to 68 days in Q2 2026 from 78 days a year earlier, per financial statements, while DPO rose to 54 days from 51 days, indicating better receivables collection and supplier payment timing.
The reduction in DSO from 92 days in Q4 2024 to 68 days in Q2 2026 suggests improved billing and collection processes, possibly due to better client relationships or contract terms. DPO has also increased, which may indicate stronger negotiating power with providers. However, the cash conversion cycle remains negative or unavailable due to missing DIO, and the volatility in working capital components warrants close monitoring.
Minimal Debt Masks Refinancing Risk
Debt-to-equity stands at 0.06 with D/EBITDA at 0.63, per reported data, indicating negligible leverage, but the slight increase in debt from prior quarters warrants monitoring.
The company's low leverage provides significant financial flexibility, but the D/EBITDA ratio has fluctuated between 0.63 and 1.67 over the past year, reflecting earnings volatility. Interest coverage is not reported, but given the low debt levels, interest expense is likely minimal. The risk is not from debt service but from potential future borrowing needs if cash flow deteriorates due to client losses.
Strong Liquidity Buffer Supports Stability
Current ratio improved to 2.14 in Q2 2026 from 2.70 a year earlier, per financial statements, while cash and equivalents stood at $152.6M, providing a solid cushion against operational shocks.
The current ratio remains above 2.0, indicating ample short-term assets to cover liabilities, even though it has declined from the peak of 3.31 in Q1 2024. The quick ratio equals the current ratio, suggesting minimal inventory dependence, which is typical for a service-based model. The cash position, combined with strong free cash flow, suggests the company can weather near-term uncertainties, including the impact of client concentration.
Misapplied P/E Overstates Earnings Power
The trailing P/E of 40.43 appears misleading given that stock-based compensation exceeded operating income in Q2 2026, per financials, suggesting reported earnings are inflated by non-cash charges.
The market often uses P/E to value PGNY, but the heavy use of SBC distorts GAAP earnings, making the P/E appear higher than the economic reality. A more appropriate metric is EV/EBITDA, which at 21.88 (or 13.24 forward) better captures the company's cash-generating ability. Investors should also consider P/FCF of 10.73, which reflects the strong cash conversion but may be flattered by working capital timing. Adjusting for SBC and client concentration is essential for a fair valuation.